JP2017506904A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017506904A5 JP2017506904A5 JP2016555603A JP2016555603A JP2017506904A5 JP 2017506904 A5 JP2017506904 A5 JP 2017506904A5 JP 2016555603 A JP2016555603 A JP 2016555603A JP 2016555603 A JP2016555603 A JP 2016555603A JP 2017506904 A5 JP2017506904 A5 JP 2017506904A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- polypeptide
- inhibitor
- cells
- pluripotent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 179
- 229920001184 polypeptide Polymers 0.000 claims description 172
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 172
- 210000004027 cell Anatomy 0.000 claims description 145
- 238000000034 method Methods 0.000 claims description 144
- 102000040430 polynucleotide Human genes 0.000 claims description 82
- 108091033319 polynucleotide Proteins 0.000 claims description 82
- 239000002157 polynucleotide Substances 0.000 claims description 82
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 63
- 239000003112 inhibitor Substances 0.000 claims description 53
- 101000971801 Homo sapiens KH domain-containing protein 3 Proteins 0.000 claims description 42
- 101000777245 Homo sapiens Undifferentiated embryonic cell transcription factor 1 Proteins 0.000 claims description 42
- 102100021450 KH domain-containing protein 3 Human genes 0.000 claims description 42
- 102100031278 Undifferentiated embryonic cell transcription factor 1 Human genes 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 42
- 230000004069 differentiation Effects 0.000 claims description 41
- 239000013598 vector Substances 0.000 claims description 39
- -1 NODAL Proteins 0.000 claims description 35
- 229940125920 TGFβR inhibitor Drugs 0.000 claims description 34
- 230000037361 pathway Effects 0.000 claims description 34
- 101000851696 Homo sapiens Steroid hormone receptor ERR2 Proteins 0.000 claims description 33
- 102100036831 Steroid hormone receptor ERR2 Human genes 0.000 claims description 33
- 102000013814 Wnt Human genes 0.000 claims description 33
- 108050003627 Wnt Proteins 0.000 claims description 33
- 239000003550 marker Substances 0.000 claims description 31
- 230000008672 reprogramming Effects 0.000 claims description 29
- 239000011435 rock Substances 0.000 claims description 29
- 229940124647 MEK inhibitor Drugs 0.000 claims description 28
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 28
- 108090000623 proteins and genes Proteins 0.000 claims description 28
- 239000000556 agonist Substances 0.000 claims description 26
- 230000014509 gene expression Effects 0.000 claims description 26
- 102000001267 GSK3 Human genes 0.000 claims description 23
- 108060006662 GSK3 Proteins 0.000 claims description 23
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical group CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 claims description 23
- 238000012258 culturing Methods 0.000 claims description 22
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 14
- 102100029284 Hepatocyte nuclear factor 3-beta Human genes 0.000 claims description 14
- 102100030634 Homeobox protein OTX2 Human genes 0.000 claims description 14
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 14
- 101001062347 Homo sapiens Hepatocyte nuclear factor 3-beta Proteins 0.000 claims description 14
- 101000584400 Homo sapiens Homeobox protein OTX2 Proteins 0.000 claims description 14
- 101000819074 Homo sapiens Transcription factor GATA-4 Proteins 0.000 claims description 14
- 101000652324 Homo sapiens Transcription factor SOX-17 Proteins 0.000 claims description 14
- 102100021380 Transcription factor GATA-4 Human genes 0.000 claims description 14
- 102100030243 Transcription factor SOX-17 Human genes 0.000 claims description 14
- 230000002269 spontaneous effect Effects 0.000 claims description 14
- 101150050863 T gene Proteins 0.000 claims description 13
- 102100031611 Collagen alpha-1(III) chain Human genes 0.000 claims description 11
- 101000993285 Homo sapiens Collagen alpha-1(III) chain Proteins 0.000 claims description 11
- 101000648265 Homo sapiens Thymocyte selection-associated high mobility group box protein TOX Proteins 0.000 claims description 10
- 102100028788 Thymocyte selection-associated high mobility group box protein TOX Human genes 0.000 claims description 10
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 10
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 10
- 239000001963 growth medium Substances 0.000 claims description 10
- 102100038146 Homeobox protein goosecoid Human genes 0.000 claims description 8
- 101000819088 Homo sapiens Transcription factor GATA-6 Proteins 0.000 claims description 8
- 102100021382 Transcription factor GATA-6 Human genes 0.000 claims description 8
- 239000012190 activator Substances 0.000 claims description 8
- 239000002609 medium Substances 0.000 claims description 8
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 8
- 102100036013 Antigen-presenting glycoprotein CD1d Human genes 0.000 claims description 7
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 7
- 102100028226 COUP transcription factor 2 Human genes 0.000 claims description 7
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical group CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 claims description 7
- 108010020070 Cytochrome P-450 CYP2B6 Proteins 0.000 claims description 7
- 102000009666 Cytochrome P-450 CYP2B6 Human genes 0.000 claims description 7
- 108010014790 DAX-1 Orphan Nuclear Receptor Proteins 0.000 claims description 7
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 claims description 7
- 102100027274 Dual specificity protein phosphatase 6 Human genes 0.000 claims description 7
- 102100030751 Eomesodermin homolog Human genes 0.000 claims description 7
- 101150026630 FOXG1 gene Proteins 0.000 claims description 7
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 claims description 7
- 102100020871 Forkhead box protein G1 Human genes 0.000 claims description 7
- 101000716121 Homo sapiens Antigen-presenting glycoprotein CD1d Proteins 0.000 claims description 7
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 claims description 7
- 101000860860 Homo sapiens COUP transcription factor 2 Proteins 0.000 claims description 7
- 101000864646 Homo sapiens Dickkopf-related protein 1 Proteins 0.000 claims description 7
- 101001057587 Homo sapiens Dual specificity protein phosphatase 6 Proteins 0.000 claims description 7
- 101001064167 Homo sapiens Eomesodermin homolog Proteins 0.000 claims description 7
- 101001060267 Homo sapiens Fibroblast growth factor 5 Proteins 0.000 claims description 7
- 101001002170 Homo sapiens Glutamine amidotransferase-like class 1 domain-containing protein 3, mitochondrial Proteins 0.000 claims description 7
- 101001032602 Homo sapiens Homeobox protein goosecoid Proteins 0.000 claims description 7
- 101000967820 Homo sapiens Inactive dipeptidyl peptidase 10 Proteins 0.000 claims description 7
- 101001008896 Homo sapiens Inactive histone-lysine N-methyltransferase 2E Proteins 0.000 claims description 7
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 claims description 7
- 101000819111 Homo sapiens Trans-acting T-cell-specific transcription factor GATA-3 Proteins 0.000 claims description 7
- 101000843556 Homo sapiens Transcription factor HES-1 Proteins 0.000 claims description 7
- 102100040449 Inactive dipeptidyl peptidase 10 Human genes 0.000 claims description 7
- 102100027767 Inactive histone-lysine N-methyltransferase 2E Human genes 0.000 claims description 7
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 7
- 102100039019 Nuclear receptor subfamily 0 group B member 1 Human genes 0.000 claims description 7
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 claims description 7
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 claims description 7
- 102100021386 Trans-acting T-cell-specific transcription factor GATA-3 Human genes 0.000 claims description 7
- 108091007416 X-inactive specific transcript Proteins 0.000 claims description 7
- 108091035715 XIST (gene) Proteins 0.000 claims description 7
- 239000000427 antigen Substances 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 7
- 210000004748 cultured cell Anatomy 0.000 claims description 7
- 102100031188 Hephaestin Human genes 0.000 claims description 6
- 102100022599 Homeobox protein Hox-C6 Human genes 0.000 claims description 6
- 101000993183 Homo sapiens Hephaestin Proteins 0.000 claims description 6
- 101001045154 Homo sapiens Homeobox protein Hox-C6 Proteins 0.000 claims description 6
- 101000955275 Homo sapiens Multiple epidermal growth factor-like domains protein 10 Proteins 0.000 claims description 6
- 101001072247 Homo sapiens Protocadherin-10 Proteins 0.000 claims description 6
- 101001072420 Homo sapiens Protocadherin-20 Proteins 0.000 claims description 6
- 101000633629 Homo sapiens Teashirt homolog 1 Proteins 0.000 claims description 6
- 101000894428 Homo sapiens Transcriptional repressor CTCFL Proteins 0.000 claims description 6
- 102100039007 Multiple epidermal growth factor-like domains protein 10 Human genes 0.000 claims description 6
- 102100036386 Protocadherin-10 Human genes 0.000 claims description 6
- 102100036739 Protocadherin-20 Human genes 0.000 claims description 6
- 102100029223 Teashirt homolog 1 Human genes 0.000 claims description 6
- 102100021393 Transcriptional repressor CTCFL Human genes 0.000 claims description 6
- 102100028501 Galanin peptides Human genes 0.000 claims description 5
- 101000860415 Homo sapiens Galanin peptides Proteins 0.000 claims description 5
- 101000976959 Homo sapiens Transcription factor 4 Proteins 0.000 claims description 5
- 101000596771 Homo sapiens Transcription factor 7-like 2 Proteins 0.000 claims description 5
- 101000976642 Homo sapiens Zinc finger protein ZIC 4 Proteins 0.000 claims description 5
- 102100035101 Transcription factor 7-like 2 Human genes 0.000 claims description 5
- 102100023493 Zinc finger protein ZIC 4 Human genes 0.000 claims description 5
- 102000007469 Actins Human genes 0.000 claims description 4
- 108010085238 Actins Proteins 0.000 claims description 4
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 claims description 4
- 102100025745 Cerberus Human genes 0.000 claims description 4
- 102100027570 Forkhead box protein Q1 Human genes 0.000 claims description 4
- 102100029283 Hepatocyte nuclear factor 3-alpha Human genes 0.000 claims description 4
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 claims description 4
- 101000914195 Homo sapiens Cerberus Proteins 0.000 claims description 4
- 101000861406 Homo sapiens Forkhead box protein Q1 Proteins 0.000 claims description 4
- 101001062353 Homo sapiens Hepatocyte nuclear factor 3-alpha Proteins 0.000 claims description 4
- 101000595669 Homo sapiens Pituitary homeobox 2 Proteins 0.000 claims description 4
- 101000735377 Homo sapiens Protocadherin-7 Proteins 0.000 claims description 4
- 101000687911 Homo sapiens Transcription factor SOX-3 Proteins 0.000 claims description 4
- 101001047681 Homo sapiens Tyrosine-protein kinase Lck Proteins 0.000 claims description 4
- 102100036090 Pituitary homeobox 2 Human genes 0.000 claims description 4
- 102100034941 Protocadherin-7 Human genes 0.000 claims description 4
- 102100024276 Transcription factor SOX-3 Human genes 0.000 claims description 4
- 102100024036 Tyrosine-protein kinase Lck Human genes 0.000 claims description 4
- 101001062354 Xenopus tropicalis Forkhead box protein A2 Proteins 0.000 claims description 4
- 210000003205 muscle Anatomy 0.000 claims description 4
- 102100030942 Apolipoprotein A-II Human genes 0.000 claims description 3
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 3
- 101000793406 Homo sapiens Apolipoprotein A-II Proteins 0.000 claims description 3
- 210000004504 adult stem cell Anatomy 0.000 claims description 3
- 210000001082 somatic cell Anatomy 0.000 claims description 3
- 102100036949 Developmental pluripotency-associated protein 2 Human genes 0.000 claims 2
- 101000804948 Homo sapiens Developmental pluripotency-associated protein 2 Proteins 0.000 claims 2
- 102100020949 Putative glutamine amidotransferase-like class 1 domain-containing protein 3B, mitochondrial Human genes 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 102000052185 transforming growth factor beta receptor activity proteins Human genes 0.000 claims 1
- 108700015056 transforming growth factor beta receptor activity proteins Proteins 0.000 claims 1
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 47
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 47
- 239000006143 cell culture medium Substances 0.000 description 13
- 239000002299 complementary DNA Substances 0.000 description 13
- 208000031448 Genomic Instability Diseases 0.000 description 9
- 241001430294 unidentified retrovirus Species 0.000 description 8
- 230000005283 ground state Effects 0.000 description 7
- 101000967920 Homo sapiens Left-right determination factor 1 Proteins 0.000 description 6
- 101000967918 Homo sapiens Left-right determination factor 2 Proteins 0.000 description 6
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 6
- 101000976653 Homo sapiens Zinc finger protein ZIC 1 Proteins 0.000 description 6
- 102100040508 Left-right determination factor 1 Human genes 0.000 description 6
- 102100040511 Left-right determination factor 2 Human genes 0.000 description 6
- 102100030798 Transcription factor HES-1 Human genes 0.000 description 6
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 6
- 102100023497 Zinc finger protein ZIC 1 Human genes 0.000 description 6
- 108010083123 CDX2 Transcription Factor Proteins 0.000 description 5
- 102100024155 Cadherin-11 Human genes 0.000 description 5
- 102100023226 Early growth response protein 1 Human genes 0.000 description 5
- 102100032610 Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Human genes 0.000 description 5
- 102100031671 Homeobox protein CDX-2 Human genes 0.000 description 5
- 101000762236 Homo sapiens Cadherin-11 Proteins 0.000 description 5
- 101001049697 Homo sapiens Early growth response protein 1 Proteins 0.000 description 5
- 101001014590 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Proteins 0.000 description 5
- 101001014594 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms short Proteins 0.000 description 5
- 101001076604 Homo sapiens Inhibin alpha chain Proteins 0.000 description 5
- 101001014610 Homo sapiens Neuroendocrine secretory protein 55 Proteins 0.000 description 5
- 101001024120 Homo sapiens Nipped-B-like protein Proteins 0.000 description 5
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 description 5
- 101000797903 Homo sapiens Protein ALEX Proteins 0.000 description 5
- 101000830603 Homo sapiens Tumor necrosis factor ligand superfamily member 11 Proteins 0.000 description 5
- 102100025885 Inhibin alpha chain Human genes 0.000 description 5
- 241000713666 Lentivirus Species 0.000 description 5
- 102100030590 Mothers against decapentaplegic homolog 6 Human genes 0.000 description 5
- 101710143114 Mothers against decapentaplegic homolog 6 Proteins 0.000 description 5
- 241000711408 Murine respirovirus Species 0.000 description 5
- 102100035377 Nipped-B-like protein Human genes 0.000 description 5
- 102100039614 Nuclear receptor ROR-alpha Human genes 0.000 description 5
- 102100024568 Tumor necrosis factor ligand superfamily member 11 Human genes 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 241000701161 unidentified adenovirus Species 0.000 description 5
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 description 4
- 101000984042 Homo sapiens Protein lin-28 homolog A Proteins 0.000 description 4
- 102100020677 Krueppel-like factor 4 Human genes 0.000 description 4
- 102100025460 Protein lin-28 homolog A Human genes 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 101100124635 Chondrus crispus HOX gene Proteins 0.000 description 2
- 101001094098 Homo sapiens Sodium- and chloride-dependent GABA transporter 3 Proteins 0.000 description 2
- FABQUVYDAXWUQP-UHFFFAOYSA-N N4-(1,3-benzodioxol-5-ylmethyl)-6-(3-methoxyphenyl)pyrimidine-2,4-diamine Chemical compound COC1=CC=CC(C=2N=C(N)N=C(NCC=3C=C4OCOC4=CC=3)C=2)=C1 FABQUVYDAXWUQP-UHFFFAOYSA-N 0.000 description 2
- 102100035254 Sodium- and chloride-dependent GABA transporter 3 Human genes 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 101100281516 Caenorhabditis elegans fox-1 gene Proteins 0.000 description 1
- 101100098873 Chondrus crispus TUBB gene Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 230000005723 MEK inhibition Effects 0.000 description 1
- 101150114468 TUB1 gene Proteins 0.000 description 1
- 101150025182 TUBB1 gene Proteins 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 101150086731 ges-1 gene Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461947979P | 2014-03-04 | 2014-03-04 | |
| US61/947,979 | 2014-03-04 | ||
| PCT/US2015/018801 WO2015134652A1 (en) | 2014-03-04 | 2015-03-04 | Improved reprogramming methods and cell culture platforms |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018028663A Division JP2018086018A (ja) | 2014-03-04 | 2018-02-21 | 改善された再プログラム方法及び細胞培養基盤 |
| JP2019148519A Division JP7170600B2 (ja) | 2014-03-04 | 2019-08-13 | 改善された再プログラム方法及び細胞培養基盤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017506904A JP2017506904A (ja) | 2017-03-16 |
| JP2017506904A5 true JP2017506904A5 (https=) | 2018-04-05 |
| JP6722108B2 JP6722108B2 (ja) | 2020-07-15 |
Family
ID=54055848
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016555603A Active JP6722108B2 (ja) | 2014-03-04 | 2015-03-04 | 改善された再プログラム方法及び細胞培養基盤 |
| JP2018028663A Pending JP2018086018A (ja) | 2014-03-04 | 2018-02-21 | 改善された再プログラム方法及び細胞培養基盤 |
| JP2019148519A Active JP7170600B2 (ja) | 2014-03-04 | 2019-08-13 | 改善された再プログラム方法及び細胞培養基盤 |
| JP2020151081A Pending JP2021000107A (ja) | 2014-03-04 | 2020-09-09 | 改善された再プログラム方法及び細胞培養基盤 |
| JP2022062448A Active JP7516452B2 (ja) | 2014-03-04 | 2022-04-04 | 改善された再プログラム方法及び細胞培養基盤 |
| JP2023118423A Active JP7738035B2 (ja) | 2014-03-04 | 2023-07-20 | 改善された再プログラム方法及び細胞培養基盤 |
| JP2025080312A Pending JP2025114793A (ja) | 2014-03-04 | 2025-05-13 | 改善された再プログラム方法及び細胞培養基盤 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018028663A Pending JP2018086018A (ja) | 2014-03-04 | 2018-02-21 | 改善された再プログラム方法及び細胞培養基盤 |
| JP2019148519A Active JP7170600B2 (ja) | 2014-03-04 | 2019-08-13 | 改善された再プログラム方法及び細胞培養基盤 |
| JP2020151081A Pending JP2021000107A (ja) | 2014-03-04 | 2020-09-09 | 改善された再プログラム方法及び細胞培養基盤 |
| JP2022062448A Active JP7516452B2 (ja) | 2014-03-04 | 2022-04-04 | 改善された再プログラム方法及び細胞培養基盤 |
| JP2023118423A Active JP7738035B2 (ja) | 2014-03-04 | 2023-07-20 | 改善された再プログラム方法及び細胞培養基盤 |
| JP2025080312A Pending JP2025114793A (ja) | 2014-03-04 | 2025-05-13 | 改善された再プログラム方法及び細胞培養基盤 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11268069B2 (https=) |
| EP (4) | EP3114214B1 (https=) |
| JP (7) | JP6722108B2 (https=) |
| KR (4) | KR20240091064A (https=) |
| CN (3) | CN106414721A (https=) |
| AU (3) | AU2015227184B2 (https=) |
| CA (1) | CA2941004A1 (https=) |
| ES (2) | ES2966757T3 (https=) |
| PT (1) | PT3114214T (https=) |
| SG (2) | SG11201606934SA (https=) |
| WO (1) | WO2015134652A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012087965A2 (en) | 2010-12-22 | 2012-06-28 | Fate Therapauetics, Inc. | Cell culture platform for single cell sorting and enhanced reprogramming of ipscs |
| SG11201606934SA (en) * | 2014-03-04 | 2016-09-29 | Fate Therapeutics Inc | Improved reprogramming methods and cell culture platforms |
| US10023879B2 (en) * | 2014-06-04 | 2018-07-17 | Fate Therapeutics, Inc. | Minimal volume reprogramming of mononuclear cells |
| AU2016211671B2 (en) | 2015-01-26 | 2022-05-26 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| RU2018106515A (ru) | 2015-07-21 | 2019-08-21 | Зе Чилдрен'С Медикал Сентер Корпорейшн | Pd-l1-экспрессирующие гемопоэтические стволовые клетки и применения |
| SG10202111851YA (en) * | 2015-10-16 | 2021-12-30 | Fate Therapeutics Inc | Platform for the Induction & Maintenance of Ground State Pluripotency |
| US20190093072A1 (en) | 2015-10-21 | 2019-03-28 | Indiana University Research And Technology Corporation | Methods of generating human inner ear sensory epithelia and sensory neurons |
| JP6928604B2 (ja) | 2015-11-04 | 2021-09-01 | フェイト セラピューティクス，インコーポレイテッド | 万能性細胞のゲノム改変 |
| CA3003152A1 (en) | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| EP3402496A4 (en) * | 2016-01-12 | 2019-06-19 | Lonza Walkersville, Inc. | METHOD AND VECTORS FOR PRODUCING VECTOR-FREE INDUCED PLURIPOTENTER STEM CELLS |
| WO2018124118A1 (ja) * | 2016-12-27 | 2018-07-05 | 住友化学株式会社 | 人工多能性幹細胞の評価方法及び選抜方法、並びに人工多能性幹細胞の製造方法 |
| CN106754729B (zh) * | 2016-12-31 | 2020-03-17 | 内蒙古赛科星家畜种业与繁育生物技术研究院有限公司 | 利用Xist Tale抑制性转录因子制备诱导性多能干细胞的方法 |
| WO2019060708A1 (en) | 2017-09-22 | 2019-03-28 | The Children's Medical Center Corporation | TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS |
| JP7554670B2 (ja) | 2017-10-11 | 2024-09-20 | フェイト セラピューティクス，インコーポレイテッド | 一時的かつ一過性プラスミドベクター発現システムを用いる細胞のリプログラミング |
| CA3083779A1 (en) | 2017-12-22 | 2019-06-27 | Fate Therapeutics, Inc. | Enhanced immune effector cells and use thereof |
| KR20250051148A (ko) * | 2017-12-28 | 2025-04-16 | 더 제이. 데이비드 글래드스톤 인스티튜트, 어 테스터멘터리 트러스트 이스타빌리쉬드 언더 더 윌 오브 제이. 데이비드 글래드스톤 | Crispr 활성화에 의한 유도 만능 세포의 생성 |
| EP3768827A1 (en) * | 2018-03-22 | 2021-01-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for reprogramming somatic cells |
| MX2021003663A (es) | 2018-09-28 | 2021-05-28 | Harvard College | Reprogramacion celular para revertir el envejecimiento y promover la regeneracion de organos y tejidos. |
| KR102943217B1 (ko) | 2018-12-02 | 2026-03-25 | 페이트 세러퓨틱스, 인코포레이티드 | 향상된 iPSC 유래 효과기 세포를 사용한 면역요법 |
| CN109679918A (zh) * | 2018-12-25 | 2019-04-26 | 合肥中科干细胞再生医学有限公司 | 一种便捷的人诱导性多能干细胞的制备方法 |
| WO2020203712A1 (ja) * | 2019-03-29 | 2020-10-08 | 富士フイルム株式会社 | 特定細胞に分化する能力を有する多能性幹細胞の製造方法およびその応用 |
| CN110564673A (zh) * | 2019-09-26 | 2019-12-13 | 广东工业大学 | 一种干细胞培养液及其应用 |
| KR20220113349A (ko) * | 2019-12-11 | 2022-08-12 | 리페아론 게엠베하 | 생물반응기의 현탁액에서 줄기세포의 확장 |
| AU2021292695A1 (en) | 2020-06-19 | 2023-02-02 | Fate Therapeutics, Inc. | Combining iPSC-derived effector cell types for immunotherapy use |
| US20210395698A1 (en) * | 2020-06-22 | 2021-12-23 | Life Technologies Corporation | Methods and compositions for cultivating pluripotent cell suspensions |
| AU2021353586A1 (en) * | 2020-10-02 | 2023-05-11 | Fate Therapeutics, Inc. | Improved reprogramming, maintenance and preservation for induced pluripotent stem cells |
| US20230302044A1 (en) * | 2022-03-28 | 2023-09-28 | Steve Reilly | Composition to increase cellularlongevity |
| EP4504914A4 (en) | 2022-04-08 | 2026-04-29 | Fate Therapeutics Inc | Cells having solid tumor targeting backbone and use thereof |
| CA3247010A1 (en) | 2022-04-08 | 2023-10-12 | Ono Pharmaceutical Co., Ltd. | CHIMERIC ANTIGEN RECEPTOR FOR TUMOR TARGETING |
| JP2025534025A (ja) * | 2022-10-12 | 2025-10-09 | 北京大学 | 化学的リプログラミング方法及び多能性幹細胞 |
| WO2025152036A1 (en) * | 2024-01-16 | 2025-07-24 | Chiou Guang Yuh | System and method for increasing the transduction capability and reprogramming efficiency in targeting cells and tissues |
| WO2025208002A1 (en) * | 2024-03-28 | 2025-10-02 | Altos Labs, Inc. | Targeted expression of regeneration factors in aged/senescent cells |
| CN118979011A (zh) * | 2024-10-22 | 2024-11-19 | 杭州瑞普晨创科技有限公司 | 人多能干细胞单细胞的建系方法 |
Family Cites Families (155)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US5010175A (en) | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| IE66205B1 (en) | 1990-06-14 | 1995-12-13 | Paul A Bartlett | Polypeptide analogs |
| US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
| US5384253A (en) | 1990-12-28 | 1995-01-24 | Dekalb Genetics Corporation | Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| DK0641781T3 (da) | 1991-09-06 | 2000-09-18 | Yoshitomi Pharmaceutical | 4-Amino(alkyl)cyclohexan-1-carboxamidforbindelser og anvendelse af disse |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5702932A (en) | 1992-07-20 | 1997-12-30 | University Of Florida | Microinjection methods to transform arthropods with exogenous DNA |
| US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
| EP0710283A4 (en) | 1993-07-22 | 1997-07-02 | Merck & Co Inc | THE EXPRESSION OF HUMAN INTERLEUKIN-1-g (b) IN A TRANSGENIC ANIMAL |
| US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
| US5593853A (en) | 1994-02-09 | 1997-01-14 | Martek Corporation | Generation and screening of synthetic drug libraries |
| US5539083A (en) | 1994-02-23 | 1996-07-23 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid combinatorial libraries and improved methods of synthesis |
| US5656610A (en) | 1994-06-21 | 1997-08-12 | University Of Southern California | Producing a protein in a mammal by injection of a DNA-sequence into the tongue |
| US5525735A (en) | 1994-06-22 | 1996-06-11 | Affymax Technologies Nv | Methods for synthesizing diverse collections of pyrrolidine compounds |
| US5549974A (en) | 1994-06-23 | 1996-08-27 | Affymax Technologies Nv | Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| CA2245835A1 (en) | 1995-06-14 | 1997-01-03 | The Regents Of The University Of California | Novel high affinity human antibodies to tumor antigens |
| US5569588A (en) | 1995-08-09 | 1996-10-29 | The Regents Of The University Of California | Methods for drug screening |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5780448A (en) | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
| GB9807935D0 (en) | 1998-04-14 | 1998-06-10 | Univ Edinburgh | Lineage specific cells and progenitor cells |
| US5945100A (en) | 1996-07-31 | 1999-08-31 | Fbp Corporation | Tumor delivery vehicles |
| NZ513800A (en) | 1996-08-12 | 2001-09-28 | Welfide Corp | Treatment of diseases using Rho kinase inhibitors |
| US5981274A (en) | 1996-09-18 | 1999-11-09 | Tyrrell; D. Lorne J. | Recombinant hepatitis virus vectors |
| EP0981352B8 (en) | 1997-05-07 | 2009-06-17 | Pharma Mar, S.A. | Use of aplidine for the treatment of cardiovascular diseases |
| JP3626206B2 (ja) | 1997-06-13 | 2005-03-02 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | Ｓｍａｄ６及びその使用 |
| NZ501276A (en) | 1997-07-01 | 2000-10-27 | Warner Lambert Co | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors in treating proliferative disorders |
| US5994624A (en) | 1997-10-20 | 1999-11-30 | Cotton Incorporated | In planta method for the production of transgenic plants |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US20060263382A1 (en) | 1998-06-20 | 2006-11-23 | Richard Hotchkiss | Membrane-permeant peptide complexes for treatment of sepsis |
| US6800790B2 (en) | 1998-07-24 | 2004-10-05 | Carnegie Institution Of Washington | Method for maintenance and propagation of germline stem cells using members of the TFG-β family of growth factors |
| GB9819912D0 (en) | 1998-09-11 | 1998-11-04 | Univ Edinburgh | Propagation and/or derivation of embryonic stem cells |
| JP2002534380A (ja) | 1999-01-07 | 2002-10-15 | ワーナー−ランバート・カンパニー | Ｍｅｋ阻害剤による喘息の治療 |
| US6703420B1 (en) | 1999-03-19 | 2004-03-09 | Bristol-Myers Squibb Pharma Company | Amino-thio-acrylonitriles as MEK inhibitors |
| AU5250400A (en) | 1999-06-18 | 2001-01-09 | Mitsubishi Pharma Corporation | Osteogenesis promoters |
| US6730293B1 (en) | 1999-08-24 | 2004-05-04 | Cellgate, Inc. | Compositions and methods for treating inflammatory diseases of the skin |
| WO2001017562A1 (fr) | 1999-09-02 | 2001-03-15 | Yamanouchi Pharmaceutical Co., Ltd. | Agents promoteurs de l'osteogenese |
| US20020142457A1 (en) | 1999-12-28 | 2002-10-03 | Akihiro Umezawa | Cell having the potentiality of differentiation into cardiomyocytes |
| US6692736B2 (en) | 2000-03-24 | 2004-02-17 | Cell Genesys, Inc. | Cell-specific adenovirus vectors comprising an internal ribosome entry site |
| DZ3401A1 (fr) | 2000-07-19 | 2002-01-24 | Warner Lambert Co | Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques |
| US20030125344A1 (en) | 2001-03-23 | 2003-07-03 | Bayer Corporation | Rho-kinase inhibitors |
| MXPA03008659A (es) | 2001-03-23 | 2005-04-08 | Bayer Ag | Inhibidores de rho-cinasa. |
| ATE452972T1 (de) | 2001-05-01 | 2010-01-15 | Ca Nat Research Council | Induzierbares expressionssystem in eukaryotischen zellen |
| CA2461185A1 (en) | 2001-09-21 | 2003-04-03 | Japan Science And Technology Corporation | Method of screening reprogramming factor, reprogramming factor screened by the method, method of using the reprogramming factor, method of differentiating undifferentiated fused cells and method of constructing cell, tissues and organs |
| PT1456380E (pt) | 2001-11-02 | 2012-07-23 | Giuliani Int Ltd | Inibidores smad7 para o tratamento de doenças do snc |
| DE60320933D1 (de) | 2002-01-10 | 2008-06-26 | Bayer Healthcare Ag | Rho-kinase inhibitoren |
| JP4469179B2 (ja) | 2002-01-23 | 2010-05-26 | バイエル ファーマセチカル コーポレーション | Ｒｈｏキナーゼ阻害剤としてのピリミジン誘導体 |
| MXPA04007196A (es) | 2002-01-23 | 2005-06-08 | Bayer Pharmaceuticals Corp | Inhibidores de rho-quinasa. |
| ATE306810T1 (de) | 2002-03-05 | 2005-11-15 | Artemis Pharmaceuticals Gmbh | Durch inzucht erzeugte von embryonalen stammzellen abgeleitete mäuse |
| SG2013013339A (en) | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| EP1500643A4 (en) | 2002-04-03 | 2007-03-28 | Dainippon Sumitomo Pharma Co | benzamidine |
| GB0210539D0 (en) | 2002-05-08 | 2002-06-19 | Univ Edinburgh | Control of es cell self renewal and lineage specification, and medium therefor |
| ES2273047T3 (es) | 2002-10-28 | 2007-05-01 | Bayer Healthcare Ag | Fenilaminopirimidinas sustituidas con heteroariloxi como inhibidores de rho-cinasa. |
| JP2006508974A (ja) | 2002-11-15 | 2006-03-16 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 癌を治療するためのｍｅｋ阻害剤およびカペシタビン（ｃａｐｅｃｉｔａｂｉｎｅ）を含む併用化学療法 |
| US7265138B2 (en) | 2003-02-10 | 2007-09-04 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| AU2003901099A0 (en) | 2003-03-11 | 2003-03-27 | Es Cell International Pte Ltd. | Methods of inducing differentiation of stem cells |
| US20050075276A1 (en) | 2003-03-14 | 2005-04-07 | Christopher Rudd | Use of inhibitors of glycogen synthase-3 to augment CD28 dependent -T-cell responses |
| US20070010008A1 (en) | 2005-06-29 | 2007-01-11 | Tissuetech, Inc. | Ex vivo expansion of primary animal cells |
| CA2529752A1 (en) | 2003-06-20 | 2005-09-15 | The Regents Of The University Of California | Polypeptide transduction and fusogenic peptides |
| AU2004278634B2 (en) | 2003-10-03 | 2009-10-01 | Keiichi Fukuda | Method of inducing the differentiation of stem cells into cardiomyocytes |
| EP2468729B1 (en) | 2003-10-15 | 2013-12-25 | Ube Industries, Ltd. | Novel indazole derivative |
| AU2004281309A1 (en) | 2003-10-16 | 2005-04-28 | The University Court Of The University Of Edinburgh | Control of ES cell self-renewal and lineage specification, and medium therefor |
| WO2005049812A1 (en) | 2003-11-19 | 2005-06-02 | Australian Stem Cell Centre Limited | Methods for producing blood products from pluripotent cells in cell culture |
| CA2546353A1 (en) | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Bicyclic inhibitors of mek and methods of use thereof |
| US20070269412A1 (en) | 2003-12-02 | 2007-11-22 | Celavie Biosciences, Llc | Pluripotent cells |
| WO2005074643A2 (en) | 2004-01-30 | 2005-08-18 | Smithkline Beecham Corporation | Benzamide compounds useful as rock inhibitors |
| ES2400567T3 (es) | 2004-04-21 | 2013-04-10 | The University Of Chicago | Inhibidores de cinasa de la cadena ligera de miosina y su uso |
| EP1791952A4 (en) | 2004-08-13 | 2008-06-11 | Univ Georgia Res Found | COMPOSITIONS AND METHODS OF SELF-RENEWAL AND DIFFERENTIATION IN HUMAN EMBRYONAL STEM CELLS |
| US20080268533A1 (en) | 2004-08-25 | 2008-10-30 | University Of Georgia Research Foundation, Inc. | Methods and Compositions Utilizing Myc and Gsk3Beta to Manipulate the Pluripotency of Embryonic Stem Cells |
| WO2006088867A2 (en) | 2005-02-15 | 2006-08-24 | Medistem Laboratories, Incorporated | Method for expansion of stem cells |
| SG177981A1 (en) | 2005-05-18 | 2012-02-28 | Array Biopharma Inc | 4-(phenylamino)-6-oxo-1, 6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases |
| US7601699B2 (en) | 2005-08-01 | 2009-10-13 | Nupotential, Inc. | Production of reprogrammed cells with restored potential |
| WO2007030693A2 (en) | 2005-09-08 | 2007-03-15 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods for promoting stem cell proliferation and survival |
| US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
| US20090227032A1 (en) | 2005-12-13 | 2009-09-10 | Kyoto University | Nuclear reprogramming factor and induced pluripotent stem cells |
| BRPI0619794B8 (pt) | 2005-12-13 | 2022-06-14 | Univ Kyoto | Uso de um fator de reprogramação, agente para a preparação de uma célula-tronco pluripotente induzida a partir de uma célula somática e métodos para preparar uma célula- tronco pluripotente induzida método e para preparar uma célula somática e uso de células-tronco pluripotentes induzidas |
| GB0601538D0 (en) | 2006-01-26 | 2006-03-08 | Univ Birmingham | Epigenetic analysis |
| EP1992360A4 (en) | 2006-02-01 | 2010-02-17 | Univ Tokyo | COMMON USE OF A TGF BETA SIGNAL HEMMER AND AN ANTITUMORAL AGENT |
| US7541186B2 (en) | 2006-02-22 | 2009-06-02 | University Of Washington | Method of generating human retinal progenitors from embryonic stem cells |
| GB0615327D0 (en) | 2006-03-30 | 2006-09-13 | Univ Edinburgh | Culture medium containing kinase inhibitors and uses thereof |
| EP2457995A1 (en) | 2006-03-30 | 2012-05-30 | The University Court of The University of Edinburgh | Culture medium containing kinase inhibitors, and uses thereof |
| US8741643B2 (en) | 2006-04-28 | 2014-06-03 | Lifescan, Inc. | Differentiation of pluripotent stem cells to definitive endoderm lineage |
| GB2452186B (en) | 2006-05-02 | 2011-01-26 | Wisconsin Alumni Res Found | Method of differentiating stem cells into cells of the endoderm and pancreatic lineage |
| CN101595107A (zh) | 2006-06-30 | 2009-12-02 | 先灵公司 | 能提高p53活性的有取代哌啶及其用途 |
| BRPI0714409A2 (pt) | 2006-07-14 | 2013-03-12 | Novartis Ag | derivados de pirimidina como inibidores de alk-5 |
| US20080020014A1 (en) | 2006-07-19 | 2008-01-24 | Paul Consigny | Implantable devices containing nuclear receptor ligands for the treatment of vascular and related disorders |
| ZA200901914B (en) | 2006-09-22 | 2010-06-30 | Riken | Stem cell culture medium and method |
| JP2008099662A (ja) | 2006-09-22 | 2008-05-01 | Institute Of Physical & Chemical Research | 幹細胞の培養方法 |
| GB0622395D0 (en) | 2006-11-09 | 2006-12-20 | Univ Cambridge Tech | Methods relating to pluripotent cells |
| WO2008089351A1 (en) | 2007-01-17 | 2008-07-24 | Wisconsin Alumni Research Foundation | Improved culture of stem cells |
| WO2008088882A2 (en) | 2007-01-19 | 2008-07-24 | The J. David Gladstone Institutes | Methods of generating cardiomyocytes |
| CN103627671A (zh) | 2007-01-30 | 2014-03-12 | 佐治亚大学研究基金会 | 产生中内胚层细胞及多能游走细胞的方法与细胞群及用途 |
| WO2008105630A1 (en) | 2007-02-27 | 2008-09-04 | Procell Therapeutics Inc. | Combined use of cell permeable nanog and oct4 for increasing self-renewal and suppressing differentiation of stem cells |
| ES2703592T3 (es) | 2007-03-07 | 2019-03-11 | Mei Pharma Inc | Combinación de agente anticancerígeno de bencimidazol y un segundo agente anticancerígeno |
| WO2008126932A2 (en) | 2007-04-09 | 2008-10-23 | Riken | Epigenetical regulation of brain plasticity |
| ES2527444T5 (es) | 2007-04-18 | 2018-05-17 | Hadasit Medical Research Services & Development Limited | Células del epitelio pigmentario de la retina derivadas de células madre |
| US7878210B2 (en) | 2007-06-04 | 2011-02-01 | Philip Morris Usa Inc. | Cellulose acetate fiber modification |
| US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
| US9213999B2 (en) | 2007-06-15 | 2015-12-15 | Kyoto University | Providing iPSCs to a customer |
| JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
| US8815585B2 (en) | 2007-06-29 | 2014-08-26 | Cellular Dynamics International, Inc. | Automated method and apparatus for embryonic stem cell culture |
| WO2009032456A2 (en) | 2007-08-01 | 2009-03-12 | Primegen Biotech Llc | Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state |
| AU2008297011B2 (en) | 2007-08-31 | 2014-06-12 | Whitehead Institute For Biomedical Research | Wnt pathway stimulation in reprogramming somatic cells |
| AU2008297024B2 (en) | 2007-10-31 | 2014-08-28 | Kyoto University | Nuclear reprogramming method |
| US20110151447A1 (en) | 2007-11-06 | 2011-06-23 | Children's Medical Center Corporation | Method to produce induced pluripotent stem (ips) cells from non-embryonic human cells |
| JP4604076B2 (ja) | 2007-11-07 | 2010-12-22 | 国立大学法人静岡大学 | 燃料電池用電解質膜 |
| WO2009073523A2 (en) | 2007-11-29 | 2009-06-11 | Children's Hospital Of Orange County | De-differentiation of human cells |
| WO2009067757A1 (en) | 2007-11-30 | 2009-06-04 | Cytomatrix Pty Ltd | Methods of inducing pluripotency involving oct4 protein |
| AU2008329562A1 (en) | 2007-11-30 | 2009-06-04 | Cytomatrix Pty Ltd | Methods of inducing pluripotency involving Sox2 protein |
| SG188904A1 (en) | 2008-03-17 | 2013-04-30 | Scripps Research Inst | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
| US20110061118A1 (en) | 2008-03-17 | 2011-03-10 | Helmholtz Zentrum Munchen | Vectors and methods for generating vector-free induced pluripotent stem (ips) cells using site-specific recombination |
| CN101550406B (zh) | 2008-04-03 | 2016-02-10 | 北京大学 | 制备多潜能干细胞的方法,试剂盒及用途 |
| WO2010013845A1 (en) * | 2008-07-30 | 2010-02-04 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
| US8298825B1 (en) | 2008-08-25 | 2012-10-30 | The General Hospital Corporation | TGF-beta receptor inhibitors to enhance direct reprogramming |
| EP2356213B1 (en) | 2008-11-04 | 2019-05-29 | Viacyte, Inc. | Stem cell aggregate suspension compositions and methods for differentiation thereof |
| EP4585589A3 (en) | 2008-12-03 | 2025-11-19 | The Scripps Research Institute | Stem cell cultures |
| BRPI0922572A2 (pt) | 2008-12-17 | 2019-09-24 | Scripps Research Inst | método para cultivar células pluripotentes, cultura de células de mamífero pluripotentes, meio de cultura de célula, célula animal pluripotente isolada, e, método para aumentar a pluripotência de uma célula de mamífero. |
| CA2688804A1 (en) * | 2008-12-17 | 2010-06-17 | The Uab Research Foundation | Polycistronic vector for human induced pluripotent stem cell production |
| CN101792776B (zh) * | 2009-02-01 | 2013-12-11 | 中国人民解放军第二军医大学东方肝胆外科医院 | 一种高效诱导多能性干细胞的重组腺病毒载体、使用该载体的诱导方法及其用途 |
| WO2010102267A2 (en) | 2009-03-06 | 2010-09-10 | Ipierian, Inc. | Tgf-beta pathway inhibitors for enhancement of cellular reprogramming of human cells |
| KR20110134939A (ko) * | 2009-04-03 | 2011-12-15 | 더 맥클린 하스피털 코퍼레이션 | 유도된 다능성 줄기 세포 |
| CN102395672A (zh) | 2009-04-13 | 2012-03-28 | 加利福尼亚大学董事会 | 用于干细胞培养的方法和组合物 |
| CA2763482A1 (en) | 2009-05-27 | 2010-12-02 | The Salk Institute For Biological Studies | Generation of genetically corrected disease-free induced pluripotent stem cells |
| US8524498B2 (en) | 2009-05-29 | 2013-09-03 | The General Hospital Corporation | Methods and compositions for homologous recombination in human cells |
| US9005975B2 (en) | 2009-05-29 | 2015-04-14 | Kyoto University | Method for selecting clone of induced pluripotent stem cells |
| DK2438160T3 (en) | 2009-06-05 | 2016-01-11 | Cellular Dynamics Int Inc | Reprogramming of T cells and hematopoietic cells |
| KR101774206B1 (ko) | 2009-08-07 | 2017-09-04 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 유도된 다능성 줄기 세포의 효율적인 확립 방법 |
| AU2010306627B2 (en) | 2009-10-16 | 2014-07-17 | The Scripps Research Institute | Induction of pluripotent cells |
| CA2779310C (en) | 2009-10-31 | 2021-11-30 | New World Laboratories Inc. | Methods for reprogramming cells and uses thereof |
| ES2539487T3 (es) | 2009-11-04 | 2015-07-01 | Cellular Dynamics International, Inc. | Reprogramación episómica con compuestos químicos |
| EP3633025B1 (en) * | 2009-11-12 | 2022-09-14 | Technion Research & Development Foundation Ltd. | Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state |
| US9005967B2 (en) | 2010-01-22 | 2015-04-14 | Kyoto University | Myc variants improve induced pluripotent stem cell generation efficiency |
| US20130011918A1 (en) | 2010-02-17 | 2013-01-10 | Biotime Inc. | Methods for telomere length and genomic dna quality control and analysis in pluripotent stem cells |
| WO2011109695A1 (en) | 2010-03-05 | 2011-09-09 | Texas Heart Institute | Ets2 and mesp1 generate cardiac progenitors from fibroblasts |
| CA2800498C (en) | 2010-03-31 | 2021-11-16 | The Scripps Research Institute | Reprogramming cells |
| US20110306516A1 (en) | 2010-06-15 | 2011-12-15 | The New York Stem Cell Foundation | Methods for producing induced pluripotent stem cells |
| JPWO2011158852A1 (ja) | 2010-06-15 | 2013-08-19 | 国立大学法人 東京大学 | 誘導型多能性幹細胞の製造方法 |
| JP5984217B2 (ja) | 2010-06-15 | 2016-09-06 | セルラー ダイナミクス インターナショナル， インコーポレイテッド | 少量の末梢血からの人工多能性幹細胞の作製 |
| WO2012018933A2 (en) | 2010-08-04 | 2012-02-09 | Cellular Dynamics International, Inc. | Reprogramming immortalized b cells |
| DK3257943T3 (da) * | 2010-11-02 | 2019-10-21 | Helmholtz Zentrum Infektionsforschung Gmbh | Fremgangsmåder og vektorer til celleimmortalisering |
| WO2012087965A2 (en) | 2010-12-22 | 2012-06-28 | Fate Therapauetics, Inc. | Cell culture platform for single cell sorting and enhanced reprogramming of ipscs |
| US9458131B2 (en) * | 2011-11-08 | 2016-10-04 | Emory University | Compounds and compositions used to epigenetically transform cells and methods related thereto |
| CA2858069C (en) | 2011-12-08 | 2020-02-11 | Novartis Ag | Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells |
| WO2013159103A1 (en) * | 2012-04-20 | 2013-10-24 | Whitehead Institute For Biomedical Research | Programming and reprogramming of cells |
| EP2853590B1 (en) | 2012-05-22 | 2018-11-07 | The University of Tokyo | Method for producing antigen-specific t cells |
| US9166832B1 (en) | 2013-10-04 | 2015-10-20 | Altera Corporation | Methods and apparatus for decision feedback equalization adaptation |
| SG11201606934SA (en) | 2014-03-04 | 2016-09-29 | Fate Therapeutics Inc | Improved reprogramming methods and cell culture platforms |
| SG10202111851YA (en) | 2015-10-16 | 2021-12-30 | Fate Therapeutics Inc | Platform for the Induction & Maintenance of Ground State Pluripotency |
| JP6928604B2 (ja) | 2015-11-04 | 2021-09-01 | フェイト セラピューティクス，インコーポレイテッド | 万能性細胞のゲノム改変 |
-
2015
- 2015-03-04 SG SG11201606934SA patent/SG11201606934SA/en unknown
- 2015-03-04 KR KR1020247017657A patent/KR20240091064A/ko active Pending
- 2015-03-04 CN CN201580019490.2A patent/CN106414721A/zh active Pending
- 2015-03-04 ES ES15757753T patent/ES2966757T3/es active Active
- 2015-03-04 CN CN202510673045.3A patent/CN120536341A/zh active Pending
- 2015-03-04 KR KR1020167027112A patent/KR102340553B1/ko active Active
- 2015-03-04 ES ES20207188T patent/ES3050608T3/es active Active
- 2015-03-04 CA CA2941004A patent/CA2941004A1/en active Pending
- 2015-03-04 EP EP15757753.7A patent/EP3114214B1/en active Active
- 2015-03-04 EP EP20207188.2A patent/EP3805369B1/en active Active
- 2015-03-04 CN CN202510672919.3A patent/CN120536340A/zh active Pending
- 2015-03-04 US US15/123,217 patent/US11268069B2/en active Active
- 2015-03-04 KR KR1020227037255A patent/KR102670874B1/ko active Active
- 2015-03-04 SG SG10201807292YA patent/SG10201807292YA/en unknown
- 2015-03-04 EP EP25191540.1A patent/EP4647498A3/en active Pending
- 2015-03-04 EP EP19194652.4A patent/EP3604499A1/en not_active Withdrawn
- 2015-03-04 PT PT157577537T patent/PT3114214T/pt unknown
- 2015-03-04 WO PCT/US2015/018801 patent/WO2015134652A1/en not_active Ceased
- 2015-03-04 JP JP2016555603A patent/JP6722108B2/ja active Active
- 2015-03-04 AU AU2015227184A patent/AU2015227184B2/en active Active
- 2015-03-04 KR KR1020217027766A patent/KR102460549B1/ko active Active
-
2018
- 2018-02-21 JP JP2018028663A patent/JP2018086018A/ja active Pending
-
2019
- 2019-08-13 JP JP2019148519A patent/JP7170600B2/ja active Active
-
2020
- 2020-09-09 JP JP2020151081A patent/JP2021000107A/ja active Pending
-
2021
- 2021-08-19 AU AU2021218109A patent/AU2021218109B2/en active Active
-
2022
- 2022-01-19 US US17/579,169 patent/US20220228125A1/en active Pending
- 2022-04-04 JP JP2022062448A patent/JP7516452B2/ja active Active
-
2023
- 2023-07-20 JP JP2023118423A patent/JP7738035B2/ja active Active
-
2024
- 2024-07-31 AU AU2024205273A patent/AU2024205273A1/en active Pending
-
2025
- 2025-05-13 JP JP2025080312A patent/JP2025114793A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017506904A5 (https=) | ||
| JP7738035B2 (ja) | 改善された再プログラム方法及び細胞培養基盤 | |
| Theunissen et al. | Molecular control of induced pluripotency | |
| US12351831B2 (en) | Platform for the induction and maintenance of ground state pluripotency | |
| US10954529B2 (en) | Minimal volume reprogramming of mononuclear cells | |
| JP7591219B2 (ja) | 誘導多能性幹細胞の製造方法及びキット | |
| Gillich et al. | Switching stem cell state through programmed germ cell reprogramming | |
| HK40104817A (zh) | 用於诱导和维护基态多能性的平台 | |
| HK40051615B (en) | Improved reprogramming methods and cell culture platforms | |
| HK40051615A (en) | Improved reprogramming methods and cell culture platforms | |
| HK40012687A (en) | Improved reprogramming methods and cell culture platforms |